Thousand Oaks Biopharmaceuticals
Thousand Oaks Biopharmaceuticals, often referred to as TO Biopharm, is a leading player in the biopharmaceutical industry, headquartered in China (CN). Established in 2005, the company has made significant strides in the development of innovative therapies, focusing primarily on biologics and biosimilars. With a strong operational presence across Asia and Europe, TO Biopharm is dedicated to addressing unmet medical needs through advanced research and development. The company’s core offerings include a range of monoclonal antibodies and recombinant proteins, distinguished by their high efficacy and safety profiles. Thousand Oaks Biopharmaceuticals has garnered recognition for its commitment to quality and innovation, positioning itself as a trusted partner in the global healthcare landscape. With a robust pipeline and a focus on sustainable growth, TO Biopharm continues to contribute to the evolution of biopharmaceutical solutions.
DitchCarbon Score
How does Thousand Oaks Biopharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Thousand Oaks Biopharmaceuticals's score of 0 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Thousand Oaks Biopharmaceuticals's reported carbon emissions
Thousand Oaks Biopharmaceuticals, headquartered in CN, currently does not have publicly available carbon emissions data for the most recent year. As a result, specific figures regarding their emissions in kg CO2e, including Scope 1, 2, or 3 emissions, are not provided. In the absence of detailed emissions data, it is important to note that the company has not outlined any specific reduction targets or initiatives related to carbon emissions. There are no commitments to the Science Based Targets initiative (SBTi) or other climate pledges mentioned, indicating a potential area for future development in their sustainability strategy. As the biopharmaceutical industry increasingly focuses on climate commitments, Thousand Oaks Biopharmaceuticals may benefit from establishing clear emissions reduction goals and strategies to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Thousand Oaks Biopharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
